Redeye provides a research update following the Q4 report published by Alzinova earlier today. The report contained no major surprises, with financials in line with our expectations. However, the company has now completed its rights issue and bolstered its cash position as it continues preparations ahead of an upcoming phase II study and seeks a partnering deal for ALZ-101.
LÄS MER
